scRNA-Seq and Bulk-Seq Analysis Identifies S100A9 Plasma Cells as a Potentially Effective Immunotherapeutic Agent for Multiple Myeloma
Xinyi Long,Fangfang Li,Sishi Tang,Jing Liu,Yunfeng Fu,Yanhui Feng
DOI: https://doi.org/10.2147/jir.s452062
IF: 4.5
2024-03-09
Journal of Inflammation Research
Abstract:Xinyi Long, 1 Fangfang Li, 1 Sishi Tang, 1 Jing Liu, 1 Yunfeng Fu, 2 Yanhui Feng 3 1 Department of Hematology, The Third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China; 2 Department of Blood Transfusion, The Third Xiangya Hospital of Central South University, Changsha, 410013, People's Republic of China; 3 Department of Oncology, The Third Xiangya Hospital of Central South University, Changsha, 410013, People's Republic of China Correspondence: Yanhui Feng, Department of Oncology, The Third Xiangya Hospital, Central South University, No. 138 Tongzipo Road, Yuelu District, Hexi, Changsha, Hunan Province, People's Republic of China, Tel +86-13549656766, Email Purpose: Immunological regimens are an important area of research for treating multiple myeloma (MM). Plasma cells play a crucial role in immunotherapy. Patients and Methods: In our study, we used both single-cell RNA sequencing (scRNA-seq) and bulk sequencing techniques to analyze MM patients. We analyzed each sample using gene set variation analysis (GSVA) based on immune-related gene sets. We also conducted further analyses to compare immune infiltration, clinical characteristics, and expression of immune checkpoint molecules between the H-S100A9 and L-S100A9 groups of MM patients. Results: We identified eight subpopulations of plasma cells, with S100A9 plasma cells being more abundant in patients with 1q21 gain and 1q21 diploid. CellChat analysis revealed that GAS and HGF signaling pathways were prominent in intercellular communication of S100A9 plasma cells. We identified 14 immune-related genes in the S100A9 plasma cell population, which allowed us to classify patients into the H-S100A9 group or the L-S100A9 group. The H-S100A9 group showed higher ESTIMATE, immune and stroma scores, lower tumor purity, and greater immune checkpoint expression. Patients with 1q21 gain and four or more copies had the lowest ESTIMATE score, immune score, stroma score, and highest tumor purity. Drug sensitivity analysis indicated that the H-S100A9 group had lower IC50 values and greater drug sensitivity compared to the L-S100A9 group. Quantitative reverse transcription (RT-q) PCR showed significantly elevated expression of RNASE6, LYZ, S100A8, S100A9, and S100A12 in MM patients compared to the healthy control group. Conclusion: Our study has identified a correlation between molecular subtypes of S100A9 plasma cells and the response to immunotherapy in MM patients. These findings improve our understanding of tumor immunology and provide guidance for developing effective immunotherapy strategies for this patient population. Keywords: multiple myeloma, single-cell sequencing, bulk transcription, tumor immune microenvironment, S100A9 Multiple myeloma (MM) is a malignant proliferative disease that manifests with symptoms including hypercalcemia, anemia, bone pain, and renal dysfunction, which significantly impact the patient's health status. 1 While the exact etiology of MM remains incompletely understood, it is recognized that its occurrence and progression are influenced by various factors, including chromosomal abnormalities, genetic factors, and immune disorders. 1 In recent years, researchers have conducted comprehensive investigations into the molecular genetics, immunology, cell biology, pathology, and other aspects of MM. This research has yielded more precise and effective approaches for understanding the disease's pathogenesis, diagnosis, and treatment. The primary treatment modalities for MM consist of induction therapy and maintenance therapy. Induction therapy involves the use of injectable proteasome inhibitors, oral immunomodulatory agents, and dexamethasone. A combination of induction therapy and autologous hematopoietic stem cell transplantation, followed by lenalidomide maintenance therapy, is recommended for eligible patients. 2 The introduction of proteasome inhibitors, such as bortezomib, has greatly enhanced the prognosis of patients diagnosed with multiple myeloma. However, a subset of patients have exhibited resistance to bortezomib treatment. Consequently, there is a need to explore alternative treatment approaches, including combination therapy and immunotherapy, in order to overcome this resistance. 3 Prior research indicates that the combination of bortezomib and hydroxychloroquine treatment should be coupled with an anti-angiogenic drug to counteract the pro-angiogenic impact of bortezomib. This approach aims to inhibit the proliferation of a small residual tumor PC clone, thereby mitigating the risk of relapse. 3 Recently, immunotherapy offers distinct advantages such as minimal -Abstract Truncated-
immunology